secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001437749-25-019219
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity enrolls first patient in Phase 2 stenoparib trial for advanced ovarian cancer
--------------------------------------------------------------------------------

- First patient dosed in new Phase 2 protocol for platinum-resistant or platinum-ineligible advanced ovarian cancer.
- Trial includes DRP companion diagnostic to enrich for stenoparib responders.
- Two patients remain on prior Phase 2 study on twice-daily dosing, deriving benefit beyond 20 months.
- Additional dosing level added aligning with FDA Project Optimus to inform pivotal trial design.
- Company expects significant clinical data by late summer 2026; pursuing accelerated regulatory pathways.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925019219/0001437749-25-019219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925019219/allr20250602_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-019219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer